Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Akebia's lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia-inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIFα and therefore improved production of hemoglobin and red blood cells.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
90 (est)+43%
Website
akebia.com
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US

Akebia Therapeutics Office Locations

Akebia Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1100 245 First St

Akebia Therapeutics Data and Metrics

Akebia Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(44.5 m)

EBIT (Q1, 2017)

(45 m)

Market capitalization (21-Jul-2017)

541.3 m

Cash (31-Mar-2017)

87.3 m
Akebia Therapeutics's current market capitalization is $541.3 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

25.4 m43 m115.8 m

General and administrative expense

12.5 m18.5 m22.2 m

Operating expense total

37.9 m61.5 m138 m

EBIT

(37.9 m)(61.5 m)(136.5 m)

Interest expense

206 k510 k

Interest income

206 k510 k901 k

Net Income

(37 m)(60.7 m)(135.7 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

7.5 m7.2 m15.8 m20.2 m30.9 m31.2 m60 m

General and administrative expense

3.4 m3.7 m3.9 m5.8 m5.3 m4.9 m5.8 m

Operating expense total

10.9 m10.9 m19.7 m26 m36.2 m36.2 m65.8 m

EBIT

(10.9 m)(10.9 m)(19.7 m)(26 m)(36.2 m)(36.2 m)(45 m)

Interest expense

96 k116 k139 k234 k

Interest income

96 k116 k139 k234 k270 k219 k435 k

Net Income

(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)
USDFY, 2014FY, 2015FY, 2016

Cash

32.8 m49.8 m187.3 m

Accounts Receivable

48 k933 k

Inventories

1.5 m2.6 m2.2 m

Current Assets

110.5 m141 m296.3 m

PP&E

209.9 k540 k2.6 m

Total Assets

111 m142.9 m300.2 m

Accounts Payable

2 m2.3 m2 m

Current Liabilities

6.9 m11.9 m114.3 m

Total Liabilities

232.1 m

Additional Paid-in Capital

205 m292.8 m365.3 m

Retained Earnings

(100.7 m)(161.4 m)(297.1 m)

Total Equity

104.1 m131 m68.1 m

Financial Leverage

1.1 x1.1 x4.4 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

27.9 m76.2 m66.7 m43.4 m46.2 m65.8 m87.3 m

Accounts Receivable

74 k48 k14 k

Current Assets

102.7 m155 m158.8 m219.5 m192.5 m165.1 m255.1 m

PP&E

404 k398 k479 k629 k1.8 m2.7 m2.9 m

Total Assets

103.5 m155.7 m159.6 m221.4 m195.6 m169.1 m259.3 m

Accounts Payable

4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m

Current Liabilities

8.8 m5.9 m14.2 m13.4 m20.9 m26.1 m133.5 m

Additional Paid-in Capital

206.1 m272 m287.1 m355.1 m356.2 m360 m372.5 m

Retained Earnings

(111.4 m)(122.1 m)(141.5 m)(187.2 m)(223 m)(259.3 m)(341.7 m)

Total Equity

94.6 m149.8 m145.4 m167.8 m133.3 m100.7 m30.6 m

Financial Leverage

1.1 x1 x1.1 x1.3 x1.5 x1.7 x8.5 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(37 m)(60.7 m)(135.7 m)

Depreciation and Amortization

49.4 k96 k296 k

Accounts Receivable

87 k

Inventories

(773 k)(1 m)428 k

Accounts Payable

4.1 m231 k(274 k)

Cash From Operating Activities

(27.5 m)(52.4 m)57.9 m

Purchases of PP&E

(229 k)(414 k)(2.7 m)

Cash From Investing Activities

(65.4 m)(13.7 m)12.7 m

Cash From Financing Activities

104.4 m83.1 m66.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)

Accounts Receivable

114 k57 k74 k48 k14 k

Accounts Payable

1.5 m3 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m
Y, 2017

Financial Leverage

8.5 x

Akebia Therapeutics Market Value History

Akebia Therapeutics Job Categories

Akebia Therapeutics Online and Social Media Presence

Akebia Therapeutics Company Life and Culture

You may also be interested in